📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
NEUTRAL
TOTAL VIEWS
17
CELC Latest News & AI Sentiment Analysis
1 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
Celcuity Inc. (CELC) announced a scheduled release of second quarter 2026 financial results on August 13, 2026, followed by a management...
Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript
CELC received FDA approval for REVTORPYK, a targeted oncology therapeutic for advanced hormone receptor-positive, HER2-negative breast...
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Celcuity (CELC) has secured FDA approval for REVTORPYK™ (gedatolisib), a targeted therapy addressing a previously underserved patient...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice